English
  • Enlicitide

    Enlicitide

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
    Enlicitide 2407527-14-2 2027

     

    [Indication] 

    1. Hypercholesterolemia: As an adjunct to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolemia.

    2. Heterozygous familial hypercholesterolemia (HeFH): For the treatment of adult patients with heterozygous familial hypercholesterolemia (HeFH).

    inquirydetail
  • Etrasimod

    Etrasimod

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
    Etrasimod  1206123-37-6  Jun, 2026  Mar.05, 2030 PV Completion

     

    [Indication] 

    Ulcerative colitis (UC): For the treatment of moderately to severely active ulcerative colitis (UC) in adults.

    inquirydetail
  • Etelcacetide

    Etelcacetide

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Etelcacetide 1262780-97-1 Oct, 2026  Feb.7, 2031 estimated PV Completion – Apr, 2026

     

    [Indication]

    It is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

    inquirydetail
  • Eltrombopag Olamine

    Eltrombopag Olamine

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Eltrombopag Olamine 496775-62-3 37134  May.20, 2023 Commercial Production

     

    [Indication]

    1. For the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

    2. For the treatment of patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy.

    3. For the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.

    inquirydetail
  • Elagolix Sodium

    Elagolix Sodium

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Elagolix Sodium 834153-87-6 36738  Jul.06, 2024 PV Completion

     

    [Indication]

    For the management of moderate to severe pain associated with endometriosis.

    inquirydetail
  • Ezetimibe

    Ezetimibe

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Ezetimibe 163222-33-1 24511, 35963 Commercial Production

     

    [Indication]

    1. In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in adults with primary (heterozygous familial and non-familial) hyperlipidemia.

    2. In combination with a statin, as an adjunct to diet to reduce elevated LDL-C, total-C, and Apo B in adults and pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).

    3. As an adjunct to diet for the treatment of patients with homozygous familial sitosterolemia (phytosterolemia), to reduce elevated sitosterol and campesterol levels.

    4. In combination with a statin, as an adjunct to diet, for the treatment of patients with established atherosclerotic cardiovascular disease (ASCVD) to reduce elevated LDL-C.

    inquirydetail
  • Enalaprilat

    Enalaprilat

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Enalaprilat 76420-72-9 Commercial Production

     

    [Indication]

    1. For the treatment of hypertension when oral administration of enalapril is not practical.

    2. For the treatment of congestive heart failure, particularly in patients who are unable to take oral medications.

    inquirydetail